Results 41 to 50 of about 5,671 (151)

Clinical Impact of Gleason Pattern 5 on Doublet Versus Triplet Therapy in Metastatic Hormone‐Sensitive Prostate Cancer

open access: yesThe Prostate, Volume 86, Issue 14, Page 1461-1469, October 2026.
ABSTRACT Background Upfront treatment intensification with androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor has become a standard approach for metastatic hormone‐sensitive prostate cancer (mHSPC). However, prognosis remains poor for some patients despite second‐generation androgen receptor antagonist‐based doublet therapy.
Saizo Fujimoto   +14 more
wiley   +1 more source

Effects of Docetaxel and Abiraterone Acetate on Nrf2 Expression in Androgen-Sensitive and Androgen-Insensitive Prostate Cancer Cells

open access: yesAhi Evran Medical Journal
Purpose: Docetaxel and Abiraterone acetate are the drugs of choice, especially for cases of prostate cancer that are insensitive to androgen deprivation therapy.
Hakan Soylu, Damla Irmak
doaj   +1 more source

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison

open access: yesClinical Medicine Insights: Oncology, 2014
Introduction This study aims to make an indirect comparison between enzalutamide and abiraterone acetate for mCRPC post-docetaxel. Methods A search for published phase 3 trials was performed with PubMed.
Pui S. Tan   +4 more
doaj   +1 more source

Phytochemical Profiling and Evaluation of Antibacterial, Anticancer, Anti‐inflammatory, and Wound‐Healing Activities of Endophytic Fungi Isolated From Atalantia racemosa

open access: yesChemistry &Biodiversity, Volume 23, Issue 9, September 2026.
ABSTRACT Endophytic fungi are recognized as prolific sources of structurally diverse secondary metabolites with significant pharmaceutical potential. In the present study, endophytic fungi were isolated from healthy tissues of Atalantia racemosa (Rutaceae), an ethnomedicinal plant traditionally used for respiratory disorders and blood purification.
Sushma M   +3 more
wiley   +1 more source

Prostate Cancer Development, Progression, and Therapy

open access: yesMedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin   +9 more
wiley   +1 more source

Validated LC-MS/MS method for the quantification of olaparib and abiraterone acetate in human plasma

open access: yesJournal of Applied Pharmaceutical Research
Background: Olaparib and Abiraterone acetate are approved in combination therapy for metastatic castration-resistant prostate cancer (mCRPC). Accurate and simultaneous quantification of these agents in plasma is crucial for pharmacokinetic assessment and
Bhavik Jani, Hitesh Vekariya
doaj   +1 more source

Very Fast Recovery of Acute Disseminated Intravascular Coagulation with Abiraterone Acetate in a Patient with Bone Metastases from Castrate-Resistant Prostate Cancer

open access: yesCase Reports in Oncology, 2014
Disseminated intravascular coagulation (DIC) is a rare, potentially life-threatening complication of advanced prostate carcinoma. We report the successful treatment with abiraterone acetate of acute DIC related to a progressive bone metastatic disease in
Hélène Gauthier   +5 more
doaj   +1 more source

Assessing the Feasibility of a Self‐Management Intervention for Individuals With Advanced Prostate Cancer and Comorbid Type II Diabetes Mellitus

open access: yesCancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Background Many older adults with cancer have at least one comorbidity. Type II diabetes mellitus (T2DM) is a common comorbidity among patients with prostate cancer (PC) and represents an important consideration in this population. Comorbid T2DM can negatively impact cancer‐specific outcomes for patients, suggesting the need for better ...
Amy L. Shaver   +15 more
wiley   +1 more source

Early‐Onset Prostate Cancer: Epidemiology, Risk Factors, Biology, Clinical Features, Management, and Early Detection

open access: yesMedComm, Volume 7, Issue 8, August 2026.
EOPC is a distinct clinicopathological entity separable from SOPC, differing fundamentally in genetic susceptibility, TMPRSS2:ERG fusion frequency, and survival outcomes. Although research remains nascent, this review provides the first comprehensive synthesis of current evidence, offering a critical foundation to guide future investigations into this ...
Xingyu Xiong   +8 more
wiley   +1 more source

Prognostic Role of Serum Neuron‐Specific Enolase at Baseline and its Early Dynamics in Metastatic Castration‐Resistant Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors

open access: yesThe Prostate, Volume 86, Issue 11, Page 1187-1194, August 2026.
ABSTRACT Background Outcomes of metastatic castration‐resistant prostate cancer (mCRPC) treated with androgen receptor signaling inhibitors (ARSIs) vary widely and may not be fully reflected by PSA and standard clinicopathologic factors. We evaluated the prognostic value of serum neuron‐specific enolase (NSE) at baseline and early on‐treatment dynamics.
Ondřej Fiala   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy